MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Melanoma (Skin)
Metastatic Melanoma
Melanoma Stage IV
Melanoma Stage III

Interventions

DRUG: [203Pb]VMT01
DRUG: [212Pb]VMT01
DRUG: Nivolumab

Sponsor

Perspective Therapeutics